All In Biotech

Drug Trial Radar · NCT07284875

Efficacy and Safety of Ribupatide in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of KAI-9531 Administered Once Weekly in Participants Living With Obesity or Overweight With Weight-Related Comorbidities Who Do Not Have Diabetes

Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruitingPivotal-lookingPhase 3. Randomized with 2,530 participants. This is a heuristic, not a regulatory label.

Status

Active, not recruiting

Enrollment

2,530

Actual

Start

Dec 18, 2025

Primary completion

Feb 2028

Study completion Mar 2028

Sponsor

Lead sponsor
KaileraIndustry
Sponsor type
Industry
First posted
Dec 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The primary objective of the study is to determine the effects of ribupatide (KAI-9531) subcutaneous (SC) injection once weekly compared to placebo on percent change in body weight.

Conditions

  • Obesity
  • Overweight

Interventions

  • RibupatideDrug

    SC Injection

  • PlaceboDrug

    SC Injection

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose 3 and 4 versus Placebo: Percent Change From Baseline in Body Weight at Week 76Time frame: Baseline, Week 76

Locations

110 sites in 10 countries. Site status is shown where the registry gives one.

  • Kailera Clinical Site

    Anniston, Alabama

  • Kailera Clinical Site

    Birmingham, Alabama

  • Kailera Clinical Site

    Cullman, Alabama

  • Kailera Clinical Site

    Sun City, Arizona

  • Kailera Clinical Site

    Escondido, California

  • Kailera Clinical Site

    Toluca Lake, California

  • Kailera Clinical Site

    Aurora, Colorado

  • Kailera Clinical Site

    Bridgeport, Connecticut

  • Kailera Clinical Site

    Jupiter, Florida

  • Kailera Clinical Site

    Lilburn, Georgia

  • Kailera Clinical Site

    Springfield, Illinois

  • Kailera Clinical Site

    Columbia, Maryland

  • Kailera Clinical Site

    Las Vegas, Nevada

  • Kailera Clinical Site

    Rochester, New York

  • Kailera Clinical Site

    Morehead City, North Carolina

  • Kailera Clinical Site

    Chickasha, Oklahoma

  • Kailera Clinical Site

    Mauldin, South Carolina

  • Kailera Clinical Site

    Chattanooga, Tennessee

  • Kailera Clinical Site

    Amarillo, Texas

  • Kailera Clinical Site

    Bellaire, Texas

  • Kailera Clinical Site

    DeSoto, Texas

  • Kailera Clinical Site

    Tomball, Texas

  • Kailera Clinical Site

    Salt Lake City, Utah

  • Kailera Clinical Site

    Danville, Virginia

  • Kailera Clinical Site

    CABA, Argentina

  • Kailera Clinical Site

    Córdoba, Argentina

  • Kailera Clinical Site

    La Plata, Buenos Aires, Argentina

  • Kailera Clinical Site #1

    San Nicolás de los Arroyos, Buenos Aires, Argentina

  • Kailera Clinical Site #2

    San Nicolás de los Arroyos, Buenos Aires, Argentina

  • Kailera Clinical Site #1

    Buenos Aires, Buenos Aires F.D., Argentina

  • Kailera Clinical Site #2

    Buenos Aires, Buenos Aires F.D., Argentina

  • Kailera Clinical Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • Kailera Clinical Site

    Buenos Aires, Buenos Aires F.D., Argentina

  • Kailera Clinical Site

    Godoy Cruz, Mendoza Province, Argentina

  • Kailera Clinical Site #1

    Rosario, Santa Fe Province, Argentina

  • Kailera Clinical Site #2

    Rosario, Santa Fe Province, Argentina

  • Kailera Clinical Site #3

    Rosario, Santa Fe Province, Argentina

  • Kailera Clinical Site

    Charlestown, New South Wales, Australia

  • Kailera Clinical Site

    Sydney, New South Wales, Australia

  • Kailera Clinical Site

    Sydney, New South Wales, Australia

Showing 40 of 110 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.